Every letter we have printed

A certificate should say what the sample was when it arrived at the laboratory. Powder, solution, sealed vial, decanted aliquot: each supports a different conclusion, and the analytical section is silent on all of them. The best documents in my file open with a description of the container.

The date I want is not the date the document was issued but the date the injection was made. They can differ by months, and a certificate issued today from a determination performed last year describes a material that has since sat in a warehouse through a summer.

I would add that a genuine chromatogram is far harder to fabricate than a summary page, which is why the summary page is what circulates. A seller who attaches the instrument output is telling you something about their confidence before you read a single number on it.

A sample that arrives at a laboratory in an unlabelled tube tells the analyst nothing about where it came from, and the report can only ever describe what was in the tube. The certificate says the material is pure; it cannot say the material is yours.

Nothing in a laboratory report is advice and the report itself usually says so. I would like your department to keep making the same point, because a number arrives with an air of authority that a sentence of interpretation does not, and the number is the part that gets acted on.

The reference population for most intervals is a convenience sample of donors or staff, and its age and sex composition is rarely printed with the interval. Where it is, it is often not the population reading the result.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

The relationship between escalation rate and reported effects is one of the better-supported findings in the area and it is stated as folklore rather than as evidence in most discussion. The underlying data is real and it is worth citing properly.

Effects reported during titration and effects reported at steady dose are different populations of events, and pooling them across the whole study makes both harder to interpret.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

What I would most like to see is a badge that says how many determinations have been commissioned in total, not how many passed. A ratio is a fact about a supplier; a single pass is a fact about a sample.

Two services, two visual languages, no common meaning. A shield from one and a roundel from the other represent different underlying work, and the reader who has learned to recognise both has learned nothing about how they differ.

Where custody is genuinely maintained, the cost is not in the paperwork but in the handling: dedicated packaging, tracked transfer, a named recipient at each end. It is perfectly achievable and it roughly doubles the price of a determination.

The buyer-submitted result and the seller-submitted result are not the same evidence and should not be printed in the same column. Your tables do distinguish them, which I appreciate; most listings do not, and a reader comparing across sources is comparing two different experiments.

The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.

The most useful presentation of a series is a plot with the interval as a shaded band. Every laboratory has the data to produce it and almost none do, and readers are left comparing rows of numbers by eye.

Comparing results across laboratories is where readers come unstuck, because the interval belongs to the method and the method differs between analysers. A value that reads high against one laboratory’s range can sit comfortably within another’s, and neither laboratory is wrong.

Species-matched receptor is the minimum condition for a potency comparison to be meaningful, and several widely circulated tables mix figures obtained on receptors from different organisms. The mixing is not visible in the table.

Albumin binding modifies the free fraction and therefore what actually reaches the receptor, and it differs substantially between the compounds under discussion. Potency comparisons that ignore it are comparing the wrong quantity.

Subcutaneous absorption is not instantaneous and the rate depends on the depot. That is a pharmacokinetic reason for site rotation which has nothing to do with tissue irritation, and it is a more interesting reason than the one usually given.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

Timing of the final scan relative to the last dose varies between studies and is not always reported. Fluid shifts on that timescale are large enough to matter for a lean-mass measurement.

Reading the substudy protocols rather than the papers is instructive: the scan schedule, the fasting requirement and the positioning instructions are all specified and all affect the result. None of it appears in secondary coverage.

The framing of maintenance as a lower-effort phase may be the single most misleading idea in the popular coverage. Everything in the published follow-up data suggests the opposite, and the framing survives because it is the one people want to hear.

Every long arrangement eventually meets a life event that interrupts it — a move, an illness, a change of circumstances. The literature treats interruption as non-adherence; the accounts I read treat it as ordinary life, and the two vocabularies describe the same events.

The word maintenance carries an assumption that the maintained state is stable. Everything in the published record suggests it is a position held against a gradient, and the vocabulary of maintenance makes the effort involved invisible to people planning around it.

Duration is the open question underneath all of this. If the honest answer is that nobody knows how long is appropriate, that should be the sentence rather than a set of conventions presented as guidance.

I have read this department for two years and the finding that has stayed with me is how little of the long-horizon question anybody has actually studied. That is not a criticism of the coverage; it is the coverage’s main result.

Reduced activity is a plausible consequence of reduced intake and it is measured in hardly any of these studies. If total activity falls during the trial, part of the composition result is downstream of that rather than of anything else.

An activity component in a trial is also an attention component, and the two cannot be separated in an unblinded design. Some part of any benefit attributed to training is attributable to contact with the study team.

The control arm in a composition substudy is losing mass too, usually, and its composition ratio is the comparison that matters. Reporting only the active arm turns a comparative result into an absolute one.

Every method in common use estimates composition from a physical property and a model, and the models were validated in populations that differ from the ones being scanned. The measurement is a calculation and it is reported as an observation.

Absorption differs between sites, and for the long-acting molecules discussed here the difference is much less consequential than for rapid-acting insulins. The rotation advice is sound and the reason usually given for it is borrowed from a different drug class.

Rotation is recommended everywhere and the reason is tissue change over repeated use rather than anything acute. Stating the reason makes the recommendation stick in a way that repeating it does not.

Milligrams, micrograms and volume are three quantities connected by a concentration that the person must calculate, and a concentration derived from a label they cannot verify. Two of the three inputs to that arithmetic are assumptions.

Signalling downstream of this receptor branches, and a compound can favour one branch. Where a paper reports a single potency it has reported one branch and left the reader to assume the others follow.

The receptor’s structure was solved with several ligands bound and the resulting papers are freely readable. They explain a good deal that used to be described as empirical and they are cited almost nowhere outside the specialist literature.

Gastric emptying delay is often treated as a side effect and it is at least partly a mechanism of the primary effect. That reframing changes how a reader should think about the management advice, and it is worth stating explicitly rather than leaving to be inferred.

Comparison shopping in this market is conducted on price and purity, in that order, and both are single numbers. A market that compares on two scalars will not develop a third.

The market has settled on purity because purity is the value a chromatograph produces cheaply. It is a supply-side accident that has become a demand-side expectation, and nobody chose it.